Results 111 to 120 of about 34,918 (236)

PFAS properties and destruction methods: A focus on enzymatic degradation

Journal of Chemical Technology &Biotechnology, Volume 101, Issue 6, Page 1126-1152, June 2026.
Abstract Per‐ and polyfluoroalkyl substances (PFAS) are known as ‘forever’ chemicals and have lasting detrimental impact on the environment and living organisms. To understand PFAS molecules better, this review begins with an overview of PFAS definition, classifications and applications, and then provides a comprehensive summary and critical analysis ...
Guobin Liang, Hua Zhao
wiley   +1 more source

<i>In Vitro</i> characterization of narciclasine: solubility, metabolic stability, and P-glycoprotein substrate status. [PDF]

Front Pharmacol
Akkireddy R, Yang IH, Lenkalapelly S, Kshirsagar GJ, May HA, Kang MH.   +5 more
europepmc   +1 more source

Harnessing Phytochemicals for Brain Cancer Therapy: Insights Into Medulloblastoma and Glioblastoma Treatment

Phytochemical Analysis, Volume 37, Issue 4, Page 507-535, June 2026.
ABSTRACT Primary brain tumors are life‐threatening diseases. Glioblastoma is the most aggressive type with a poor prognosis. Medulloblastoma is the most common pediatric brain tumor. While surgical treatments often result in recurrences owing to the complex nature of the tumor microenvironment, conventional treatments lower the quality of life of ...
Ilkay Irem Ozbek, Mesra Aktas, Hale Saybasili, Kutlu O. Ulgen   +3 more
wiley   +1 more source

Toxicokinetic-Oriented Assessment of Nepetalactone Using In Silico ADMET Modeling, In Vitro Rat and Human Liver Microsomes, and UHPLC-MS/MS Metabolite Characterization. [PDF]

Toxics
Stoica NB, Cascajosa-Lira A, Morea A, Catunescu GM, Hornedo-Ortega R, Guzmán-Guillén R.   +5 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Model to Predict Drug–Drug Interactions With the Antibody–Drug Conjugate Trastuzumab Deruxtecan

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 6, June 2026.
ABSTRACT The topoisomerase I inhibitor payload (DXd) released from the human epidermal growth factor receptor 2‐targeted antibody–drug conjugate (ADC) trastuzumab deruxtecan (T‐DXd) is eliminated by hepatic uptake via OATP1B1/3, metabolism by CYP3A, biliary excretion via P‐glycoprotein and breast cancer resistance protein, and urinary excretion.
Akiko Watanabe, Katherine L. Gill, Kuan‐Fu Chen, Hannah M. Jones, Mailys De Sousa Mendes, Iain Gardner, Masakatsu Kotsuma   +6 more
wiley   +1 more source

Overlooked aspects of scaling enzyme activity through abundance across tissues and individuals: Insights from k_cat measurements in matched liver and intestinal samples. [PDF]

Drug Metab Dispos
Al-Majdoub ZM, Barber J, Rostami-Hodjegan A, Galetin A, Scotcher D.   +4 more
europepmc   +1 more source

Characterization of UGT Isoforms Involved in Liquiritigenin Glucuronidation in Human Liver Microsomes

, 2010
Characterization of UGT Isoforms Involved in Liquiritigenin Glucuronidation in Human Liver ...
胡莹, 杨凌, 刘慧鑫
core  

Pedunculoside Inhibits Hepatocellular Carcinoma Progression by Activating the MAPK Signaling Pathway Through Targeting and Suppressing CDK4

Phytotherapy Research, Volume 40, Issue 6, Page 3171-3189, June 2026.
Pedunculoside targets and suppresses CDK4; consequently, it activates the MAPK pathway and inhibits hepatocellular carcinoma progression. ABSTRACT Hepatocellular carcinoma (HCC) remains a major challenge in cancer prevention and treatment, highlighting the urgent need for effective and low‐toxicity anti‐HCC therapies. Recently, CDK4‐targeted inhibitors
Yang Zhou, Jingyun Chi, Yuan Ding, Zhidi Zhang, Rui Liang, Tianhao Wang, Yan Jiang, Rujun Song, Huazhou Fu, Xizhen Zhou   +9 more
wiley   +1 more source

Dietary allicin supplementation inhibits hepatic CYP3A37 in chickens: Evidence from in vitro and in vivo models. [PDF]

Poult Sci
Li Y, Yuan H, Wang J, Yin S, Qiu X, Yang H.   +5 more
europepmc   +1 more source

Nanobodies: A Promising Toolkit for Diagnostic Applications

SmartMat, Volume 7, Issue 3, June 2026.
This review focuses on camelid‐derived nanobodies (VHHs) and explains how their small size and high stability support robust diagnostic design. Applications across ELISA, lateral flow assays, and PET/SPECT imaging are summarized, along with clinical progress such as caplacizumab.
Wei Wu, Abid Ali, Li Sun, Jiahao Hu, Lina Hameed, Saba Shafi, Ali Raza, Khuzin Dinislam, Wenjing Xing, Long Rong, Jie Lin, Jian Ma   +11 more
wiley   +1 more source